Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
January 31 2022 - 6:30AM
Biogen Announces Nancy Leaming and Brian Posner to Retire from
Board of Directors
Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and
Brian Posner will retire from Biogen’s Board of Directors,
effective at the time of the Company’s 2022 annual meeting of
stockholders.
Ms. Leaming, who joined the Biogen Board in 2008, was previously
the Chief Executive Officer and President of Tufts Health Plan, a
provider of healthcare insurance. Mr. Posner, who also joined the
Biogen Board in 2008, is a private investor and founder and
Managing Partner of Point Rider Group LLC, a boutique consulting
and advisory services firm. Ms. Leaming is a member of the Biogen
Board’s Audit Committee and Mr. Posner serves as Chair of its
Compensation Management and Development Committee.
Stelios Papadopoulos, Ph.D., Chairman of the Biogen Board of
Directors, said, “For nearly 15 years, Nancy and Brian have played
important roles on our Board, guiding Biogen in its mission of
pioneering therapies that make a meaningful difference in the lives
of thousands of people worldwide. In particular, Biogen has
benefitted from Nancy’s deep experience as a leader in the
insurance space and her insights into the healthcare reimbursement
and payor market. We have relied on Brian’s significant management
and financial expertise, coupled with his commitment to
sustainability. We are grateful to Nancy and Brian for their
invaluable contributions during their many years of service and
wish them both the very best.”
Michel Vounatsos, Biogen’s Chief Executive Officer, said, “I
would like to thank Nancy and Brian for the many years of wise
counsel they have provided to the Board and our leadership team as
Biogen has grown. We wish them both well in the future and are
grateful they will remain extended members of the Biogen
community.”
Mr. Posner said, “In my 15 years on the Board, Biogen has grown
from a biotech in Cambridge to a global company that has pioneered
life changing therapies for the most complex devastating
neurodegenerative diseases, including the first treatment for
spinal muscular atrophy and most recently, the first anti-amyloid
beta medicine in Alzheimer’s disease. It has been especially
amazing to be part of the journey as Biogen has built one of the
industry’s most diversified pipelines in neuroscience and led
meaningful initiatives to address the interrelation between climate
and health.”
Ms. Leaming said, “It has been an honor to serve on the Biogen
Board of Directors alongside a group of exceptionally bright,
experienced and highly effective directors. Biogen remains
steadfast in its commitment to deliver responsibly and
transparently both for shareholders and for patients, and I look
forward to following its future progress as it continues on its
mission to pioneer and lead in neuroscience in a manner that is
beneficial to its many stakeholders.”
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has a
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and is providing the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing the
industry’s most diversified pipeline in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
The company routinely posts information that may be important to
investors on its website at www.biogen.com. To learn more,
please visit www.biogen.com and follow Biogen on social
media
– Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, about the
treatment of Alzheimer’s disease and spinal muscular atrophy;
clinical development programs, clinical trials and data readouts
and presentations; and risks and uncertainties associated with drug
development and commercialization. These statements may be
identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,”
“possible,” “potential,” “will,” “would” and other words and terms
of similar meaning. Drug development and commercialization involve
a high degree of risk, and only a small number of research and
development programs result in commercialization of a product.
Results in early stage clinical trials may not be indicative of
full results or results from later stage or larger scale clinical
trials and do not ensure regulatory approval. You should not place
undue reliance on these statements or the scientific data
presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation unexpected concerns
that may arise from additional data, analysis or results obtained
during clinical trials; the occurrence of adverse safety events;
risks of unexpected costs or delays; the risk of other unexpected
hurdles; failure to protect and enforce Biogen’s data, intellectual
property and other proprietary rights and uncertainties relating to
intellectual property claims and challenges; risks associated with
current and potential future healthcare reforms; product liability
claims; third party collaboration risks; and the direct and
indirect impacts of the ongoing COVID-19 pandemic on Biogen’s
business, results of operations and financial condition. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from Biogen’s expectations in any
forward-looking statement. Investors should consider this
cautionary statement as well as the risk factors identified in
Biogen’s most recent annual or quarterly report and in other
reports Biogen has filed with the U.S. Securities and Exchange
Commission. These statements are based on Biogen’s current beliefs
and expectations and speak only as of the date of this news
release. Biogen does not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
MEDIA CONTACT:BiogenAshleigh Koss+ 1 908 205
2572public.affairs@biogen.com |
INVESTOR CONTACT:BiogenMike Hencke+1 781 464
2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024